Aclaris Therapeutics, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
ACRS Nasdaq 2834 www.aclaristx.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Aclaris Therapeutics, Inc.

Aclaris Therapeutics First Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag - May 10th, 2025 12:10 pm
Aclaris Therapeutics to Participate in the HC Wainwright “HCW@Home” Series - May 9th, 2025 11:00 am
Aclaris Therapeutics (ACRS) Reports Q1 Loss, Misses Revenue Estimates - May 8th, 2025 12:00 pm
Aclaris: Q1 Earnings Snapshot - May 8th, 2025 10:57 am
Aclaris Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update - May 8th, 2025 10:50 am
Aclaris Therapeutics Appoints Jesse Hall, M.D. as Chief Medical Officer - Apr 29th, 2025 11:00 am
Strong week for Aclaris Therapeutics (NASDAQ:ACRS) shareholders doesn't alleviate pain of three-year loss - Apr 25th, 2025 12:16 pm
Aclaris Therapeutics receives FDA approval for Phase Ia/Ib trial of ATI-052 - Apr 23rd, 2025 10:44 am
Aclaris Therapeutics Secures U.S. Food and Drug Administration IND Clearance for ATI-052, Enabling Advancement of its Novel Bispecific Anti-TSLP/IL-4R Investigational Antibody - Apr 22nd, 2025 10:59 am
Will Aclaris Therapeutics (NASDAQ:ACRS) Spend Its Cash Wisely? - Mar 31st, 2025 12:18 pm
Aclaris Therapeutics assumed with an Overweight at Cantor Fitzgerald - Mar 19th, 2025 12:21 pm
Aclaris Therapeutics to Participate in Two March Healthcare Conferences - Mar 4th, 2025 12:00 pm
This Aclaris Therapeutics Insider Increased Their Holding By 1,537% Last Year - Mar 4th, 2025 11:46 am
Aclaris Therapeutics Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags - Mar 4th, 2025 11:21 am
Aclaris Therapeutics (ACRS) Reports Q4 Loss, Tops Revenue Estimates - Feb 27th, 2025 1:20 pm
Aclaris: Q4 Earnings Snapshot - Feb 27th, 2025 12:21 pm
Aclaris Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Corporate Update - Feb 27th, 2025 11:59 am
New Publication Highlights Unique Properties of ATI-2138, a Potent and Selective Inhibitor of ITK and JAK3 - Feb 12th, 2025 11:50 am
Aclaris Therapeutics Announces Formation of New Scientific Advisory Board - Jan 30th, 2025 9:01 pm
Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Jan 6th, 2025 9:30 pm